Logo Image
|Videos|January 31, 2019

Determining the Burden of Candidemia in the US

Sharon Tsay, MD, explains why burden estimates for candidemia are needed.

Segment Description: Sharon Tsay, MD, medical epidemiologist in the Mycotic Diseases Branch of the Centers for Disease Control and Prevention, explains why burden estimates for candidemia are needed.

Interview transcript (modified slightly for readability):

Tsay: Burden estimates are really important for us to understand what the burden of a disease is and there at this point are no existing burden estimates for candidemia in this country. So, what our group really is thought to try to put a number on how much candidemia is in the US so that's something that we can trend going forward and understand the impact of any interventions going forward and really understand how many people are affected.

Related to this article

View more
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Read more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Read more